Use of a synthetic protease inhibitor for the treatment of L-asparaginase-induced acute pancreatitis complicated by disseminated intravascular coagulation.
In two patients receiving L-asparaginase therapy, severe acute pancreatitis complicated by disseminated intravascular coagulation (DIC) developed. In both cases it was successfully treated with continuous infusion of a synthetic protease inhibitor, nafamostat mesilate. In this report, we briefly discuss the clinical efficacy of the synthetic protease inhibitor in treating such cases.
Murakawa
M
M
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Okamura
T
T
Shibuya
T
T
Harada
M
M
Otsuka
T
T
Niho
Y
Y
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D001550:Benzamidines; D003520:Cyclophosphamide / Q000008:administration & dosage; D004211:Disseminated Intravascular Coagulation / Q000139:chemically induced* / Q000150:complications; D005260:Female; D016670:Gabexate / Q000627:therapeutic use; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D010195:Pancreatitis / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011480:Protease Inhibitors / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
D001550:Benzamidines; D006146:Guanidines; D011480:Protease Inhibitors; D016670:Gabexate; D014750:Vincristine; D003520:Cyclophosphamide; D001215:Asparaginase; D011241:Prednisone; C032855:nafamostat; D008727:Methotrexate